Dasatinib first-line treatment in gastrointestinal stromal tumors. A multi center phase II trial.
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2018
At a glance
- Drugs Dasatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 09 Jan 2018 Results published in the Cancer
- 17 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 02 Jul 2012 Actual patient number is 47 as reported by ClinicalTrials.gov.